SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Demyelinating disease and vaccination of the human papillomavirus

By

[Article in Spanish] Alvarez-Soria MJ, Hernandez-Gonzalez A, Carrasco-Garcia de Leon S, Del Real-Francia MA, Gallardo-Alcaniz MJ, Lopez-Gomez JL. Source Hospital General de Ciudad Real, Ciudad Real, Espana. Abstract INTRODUCTION. Primary prevention by prophylactic vaccination against the major cause of cervical cancer, the carcinogenic human papillomavirus (HPV) types 16 and 18, is now available worldwide. Postlicensure […]

Anaphylaxis following quadrivalent human papillomavirus

By

Julia M.L. Brotherton MD MPH, Mike S. Gold MD, Andrew S. Kemp MD PhD, Peter B. McIntyre MD PhD, Margaret A. Burgess MD, Sue Campbell-Lloyd RN, on behalf of the New South Wales Health HPV Adverse Events Panel Background: In 2007, Australia implemented the National human papillomavirus (HPV) Vaccination Program, which provides quadrivalent HPV vaccine […]

Prophylactic HPV Vaccines: Current Knowledge of Impact on Gynecological Premalignancies

By

Authors:  Diane M. Harper/Karen B. Williams Published 3 July 2010, Discovery Medicine Abstract: Approaches for cervical cancer prevention are changing. Screening still remains the most effective method for cervical cancer prevention. Guidelines are moving to an older group of women to be screened less frequently with combinations of technologies that include biomarkers and cytology. HPV […]

HPV Vaccine: Debate Over Benefits, Marketing, and New Adverse Event Data

By

By:  Zosia Chustecka August 18, 2009 — The benefit of vaccinating against human papilloma virus (HPV) to prevent cervical cancer is questioned in an editorial in the Journal of the American Medical Association. “The theory behind the vaccine is sound: if HPV infection can be prevented, cancer will not occur,” writes editorialist Charlotte Haug, MD, […]

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24—45 years: a randomised, double-blind trial

By

The Lancet, Volume 373, Issue 9679, Pages 1949 – 1957, 6 June 2009 doi:10.1016/S0140-6736(09)60691-7:  Munoz, et al   Background: Although the peak incidence of human papillomavirus (HPV) infection occurs in most populations within 5—10 years of first sexual experience, all women remain at risk for acquisition of HPV infections. We tested the safety, immunogenicity, and […]

News

Videos

Contact